Samira Rasaneh1, Hossein Rajabi1, Fariba Johari Daha1. 1. 1 Department of Radioisotope, Nuclear science and Technology Research Institute, Tehran 14115-331, Iran ; 2 Department of Medical Physics, School of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran.
Abstract
OBJECTIVE: Estimation of activity accumulated in tumor and organs is very important in predicting the response of radiopharmaceuticals treatment. In this study, we synthesized (177)Lutetium ((177)Lu)-trastuzumab-iron oxide nanoparticles as a double radiopharmaceutical agent for treatment and better estimation of organ activity in a new way by magnetic resonance imaging (MRI). METHODS: (177)Lu-trastuzumab-iron oxide nanoparticles were synthesized and all the quality control tests such as labeling yield, nanoparticle size determination, stability in buffer and blood serum up to 4 d, immunoreactivity and biodistribution in normal mice were determined. In mice bearing breast tumor, liver and tumor activities were calculated with three methods: single photon emission computed tomography (SPECT), MRI and organ extraction, which were compared with each other. RESULTS: The good results of quality control tests (labeling yield: 61%±2%, mean nanoparticle hydrodynamic size: 41±15 nm, stability in buffer: 86%±5%, stability in blood serum: 80%±3%, immunoreactivity: 80%±2%) indicated that (177)Lu-trastuzumab-iron oxide nanoparticles could be used as a double radiopharmaceutical agent in mice bearing tumor. Results showed that (177)Lu-trastuzumab-iron oxide nanoparticles with MRI had the ability to measure organ activities more accurate than SPECT. CONCLUSIONS: Co-conjugating radiopharmaceutical to MRI contrast agents such as iron oxide nanoparticles may be a good way for better dosimetry in nuclear medicine treatment.
OBJECTIVE: Estimation of activity accumulated in tumor and organs is very important in predicting the response of radiopharmaceuticals treatment. In this study, we synthesized (177)Lutetium ((177)Lu)-trastuzumab-iron oxide nanoparticles as a double radiopharmaceutical agent for treatment and better estimation of organ activity in a new way by magnetic resonance imaging (MRI). METHODS: (177)Lu-trastuzumab-iron oxide nanoparticles were synthesized and all the quality control tests such as labeling yield, nanoparticle size determination, stability in buffer and blood serum up to 4 d, immunoreactivity and biodistribution in normal mice were determined. In mice bearing breast tumor, liver and tumor activities were calculated with three methods: single photon emission computed tomography (SPECT), MRI and organ extraction, which were compared with each other. RESULTS: The good results of quality control tests (labeling yield: 61%±2%, mean nanoparticle hydrodynamic size: 41±15 nm, stability in buffer: 86%±5%, stability in blood serum: 80%±3%, immunoreactivity: 80%±2%) indicated that (177)Lu-trastuzumab-iron oxide nanoparticles could be used as a double radiopharmaceutical agent in mice bearing tumor. Results showed that (177)Lu-trastuzumab-iron oxide nanoparticles with MRI had the ability to measure organ activities more accurate than SPECT. CONCLUSIONS: Co-conjugating radiopharmaceutical to MRI contrast agents such as iron oxide nanoparticles may be a good way for better dosimetry in nuclear medicine treatment.
Entities:
Keywords:
Radioimmunotherapy (RIT); activity estimation; herceptin; lutetium-177; magnetic nanoparticles; magnetic resonance imaging (MRI)
Authors: Isabelle Gardin; Lionel G Bouchet; Karine Assié; Jerome Caron; Albert Lisbona; Ludovic Ferrer; Wesley E Bolch; Pierre Vera Journal: Cancer Biother Radiopharm Date: 2003-02 Impact factor: 3.099
Authors: Adam F Prasanphanich; Lauren Retzloff; Stephanie R Lane; Prasant K Nanda; Gary L Sieckman; Tammy L Rold; Lixin Ma; Said D Figueroa; Samantha V Sublett; Timothy J Hoffman; Charles J Smith Journal: Nucl Med Biol Date: 2009-02 Impact factor: 2.408
Authors: Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram Journal: J Nucl Med Date: 2014-05-19 Impact factor: 10.057
Authors: Stig Palm; Richard M Enmon; Cornelia Matei; Katherine S Kolbert; Su Xu; Pat B Zanzonico; Ronald L Finn; Jason A Koutcher; Steven M Larson; George Sgouros Journal: J Nucl Med Date: 2003-07 Impact factor: 10.057
Authors: Martin A Funovics; Barbara Kapeller; Christoph Hoeller; Henry S Su; Rainer Kunstfeld; Stephan Puig; Karin Macfelda Journal: Magn Reson Imaging Date: 2004-07 Impact factor: 2.546